---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-047143"
form_type: "8-K"
ticker: "BLFS"
cik: "0000834365"
company_name: "BIOLIFE SOLUTIONS INC"
filed_at: "2024-11-12T23:59:59+00:00"
generated_at: "2026-05-30T02:32:30.094531+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# BioLife Solutions Q3 revenue up 30% to $30.6M; raises Cell Processing guidance to $72-73M

## Summary
- Q3 revenue $30.6M (+30% YoY); Cell Processing $19.0M (+43% YoY); adjusted EBITDA $6.1M (20% margin).
- GAAP net loss from continuing ops $1.7M vs $15.8M YoY; adj. gross margin 54% (up from 44%).
- Completed sale of SciSafe biostorage business for $73M cash on Nov 12, 2024.
- FY2024 revenue guidance revised to $98-100M; Cell Processing raised to $72-73M (previously $70-71M).
- Biostorage guidance cut to $26-27M due to SciSafe divestiture; management expects positive adjusted EBITDA for full year.

## SEC filing metadata
- accession: 0001628280-24-047143
- form_type: 8-K
- ticker: BLFS
- cik: 0000834365
- company_name: BIOLIFE SOLUTIONS INC
- filed_at: 2024-11-12T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/834365/000162828024047143/0001628280-24-047143-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/834365/000162828024047143/blfs-20241112.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-047143
- JSON: https://secwatch.observer/filing/0001628280-24-047143.json
- Plain text: https://secwatch.observer/filing/0001628280-24-047143.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.